ANGLE has completed a placing of new ordinary shares

June 2021 — ANGLE Plc has raised funds to develop the company.

ANGLE, through its subsidiaries, engages in providing products in cancer diagnostics and foetal health. Its main product is the Parsortix cell separation system, which can capture very rare cells from the blood. The company was founded by Andrew D. W. Newland in April 1994 and is headquartered in Guildford, UK.

Our role in the transaction

Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as nominated advisor and joint broker, assisted ANGLE’s management team and shareholders all the way, from the start to the successful completion of the placing. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, seeking new institutional investors, deal structuring, document drafting, liaising with the exchange and the placing pricing and sizing.